An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition

Edouard Forcade,1,2,3,4 Katelyn Paz,4 Ryan Flynn,5 Brad Griesenauer,6,7,8,9 Tohti Amet,6,7,8,9 Wei Li,6,7,8,9 Liangyi Liu,6,7,8,9 Giorgos Bakoyannis,10 Di Jiang,11 Hong Wei Chu,11 Mercedes Lobera,12 Jianfei Yang,12 David S. Wilkes,13 Jing Du,1,2 Kate Gartlan,1,2,3 Geoffrey R. Hill,14 Kelli P.A. MacDonald,14 Eduardo L. Espada,1,2 Patrick Blanco,1 Jonathan S. Serody,15 John Koreth,1,2 Corey S. Cutler,1,2 Joseph H. Antin,1,2 Robert J. Soiffer,1,2 Jerome Ritz,1,2 Sophie Paczesny,6,7,8,9 and Bruce R. Blazar5

1Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 2Harvard Medical School, Boston, Massachusetts, USA. 3Immunoconcept, CNRS UMR 5164, Bordeaux University, Bordeaux, France. 4Department of Hematology and Cell Therapy, University Hospital, Bordeaux, France. 5Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. 6Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA. 7Herman B. Wells Center for Pediatric Research, 8Department of Microbiology and Immunology, and 9Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA. 10Department of Biostatistics, Indiana University Fairbanks School of Public Health and School of Medicine, Indiana, USA. 11National Jewish Health, Denver, Colorado, USA. 12GlaxoSmithKline, Cambridge, Massachusetts, USA. 13Dean, University of Virginia, School of Medicine, Charlottesville, Virginia, USA. 14QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 15Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Introduction

Over the decades, improvements have been made in acute graft-versus-host disease (aGvHD) prevention. In contrast, chronic GvHD (cGvHD), which is often preceded by aGvHD, continues to be a significant cause of morbidity and mortality, affecting an estimated 50% of allogeneic hematopoietic stem cell...
transplantation (HSCT) patients (1, 2). Efforts have been made to characterize proteomic and cellular biomarkers to better define disease severity, predict therapeutic responses, and improve our understanding of cGvHD pathogenesis (3–7).

Donor T effector cells (Teffs) have been shown to mediate alloreactivity toward recipient tissue in both human and mouse studies (2, 8, 9) and are required elements of aGvHD and cGvHD generation. Both in vitro or in vivo T cell depletion have reduced but not eliminated cGvHD incidence, and both can be associated with increased infections and malignancy recurrence as complications. Offsetting GvHD-causing Teffs are regulatory mechanisms that serve to dampen the immune destructive responses that can harm the organism. These include cell-surface molecules such as coinhibitory receptors; metabolic control switches such as the indoleamine 2,3-dioxygenase tryptophan catabolic pathway; and cellular mechanisms such as Tregs. Relevant to cGvHD in patients, we previously showed that patients developing cGvHD presented altered Treg homeostasis with quantitative deficiency (5). Strategies to expand Tregs in vivo were efficient at reducing but not uniformly eliminating disease severity (10). Similarly, we observed abnormal homeostasis and chronically activated B cells (6, 11), offering the possibility to deplete or target them (12–14). Thus, approaches to be used in combination with Treg augmentation would be desirable. Identifying a new Teff cell involved in the pathogenesis of the disease would be a key step forward to develop prophylactic, therapeutic, and prognostic means of reducing the consequences of cGvHD in patients.

GvHD-causing Teffs can be contained within Th cell subsets that have been progressively defined according to the expression of surface markers, activation molecules, and chemokine receptors and their capacity to secrete cytokines. Nomenclature defining Th polarization (Th1, Th2, Th9, Th17, Th22, etc.) is expanding with the further complexity that Th cells maintain a degree of plasticity, being able to convert from one subset to another (15). The Th17 subset is defined according to the expression of RAR-orphan receptor β transcription factor (RORγt) (16) and the capacity to secrete IL-17 upon stimulation. In addition, different surface markers have been described, such as chemokine receptor 6 (CCR6), CD161, CCR4, IL-23R, and CDS5 to characterize the Th17 subset (17, 18). Several studies have attempted to decipher the role of Th17 in aGvHD (19, 20). However, murine models presented conflicting results, as IL-17–KO donor T cells either reduced (21) or exacerbated aGvHD (22). Similarly, human aGvHD studies reported discordant results. Indeed, blood/tissue Th17 cells were found to be either increased (23) or decreased (24, 25). Interestingly, some studies provided data suggesting Th17 involvement in the transition from aGvHD to cGvHD. Indeed, Chen et al. reported the expansion of Th17 in the early phase of aGvHD playing a role in the development of late autoimmune-like disease (26) and, in parallel, Carlson et al. described the role of Th17 in severe skin and lung injuries that resemble cGvHD (27).

With respect to the pathogenesis of cGvHD, the role of Th17 cells is less controversial. Studies have demonstrated a role for Th17 cells in murine models with features of autoimmunity (26), scleroderma (28), and multiorgan system disease with bronchiolitis obliterans (BO) in a CSF-1/CSF-1R– (29) and STAT3-dependent manner (30, 31). In humans, there is a paucity of data. Dander et al. showed an increase of Th17 cells in the blood of patients with active cGvHD (23), and a mixed Th1/Th17 signature was observed in the skin of patients with active disease (32). More recently, we identified candidate biomarkers (CCL14 and CD146) in the plasma of patients developing gastrointestinal (GI) GvHD that revealed an activated Th17-prone T cell population (CD4+CD146+CCR5+ T cells) participating in the pathogenesis of aGvHD (33). Interestingly, CD146 appeared associated with cGvHD in our recent large-scale proteomic study (7). Altogether, these data suggest studying the role of Th17 cells and the RORγt pathway during cGvHD pathogenesis, and targeting this subset may provide a clinical benefit.

Strategies specifically targeting the Th17 subset have included antibody-mediated neutralization of IL-17 or IL-23 and were predominantly evaluated in the field of autoimmune diseases (34–36). The Th17 program is dependent on the master regulator RORγt and STAT3 signaling. Dual RORγt or STAT3 pathway inhibitors have been developed, such as the small GTPase, p-associated coiled-coil containing protein kinase 2 (Rock2) inhibitor, KD005. We recently showed that KD005 was efficient in suppressing murine and human cGvHD through inhibition of RORγt and STAT3, leading to reduced IL-17 and IL-21 cytokine production and T follicular helper (TFH) cells that can support pathogenic antibody production during cGvHD (31, 37). Via its effects on STAT5, Treg production also is facilitated (31, 38). Other inhibitors can provide a more specific approach by targeting the Th17 program (e.g., RORγt), only without affecting all downstream STAT3 signaling (e.g., TFH and Th17), in order to preserve other immune functions such as humoral immunity (STAT3/4-dependent) (39, 40). One such small-molecule RORγt inhibitor is TMP778,
which acts through several modalities: interruption of RORγt binding its target genes, disrupting RORγt interaction with other transcription factors or coactivators, and promotion of Gata3 transactivation (40). Previous reports demonstrated the role of TMP778 interfering with Th17 cell differentiation and its activity during mouse models of autoimmune diseases (40, 41). Molecular studies showing a STAT3-dependent mechanism of action suggest RORγt inhibitor use as a candidate treatment of cGVHD.

Here, we show that CD146-expressing cells are increased in the context of cGVHD in both human and mice, and they harbor a Th17 polarization with upregulation of RORγt and increased capacity to secrete IL-17. This population was required for cGVHD pathogenesis, as CD146 KO, anti–IL-17 neutralizing antibody, and RORγt-specific inhibition (TMP778) each alleviated disease severity. Altogether, our data support that RORγt inhibitors could be used as a new therapeutic option for cGVHD.

**Results**

**Increased frequencies of CD146⁺ and CD146⁺CCR5⁺ CD4 T cell subsets during cGVHD.** CD146 and CCR5 represent 2 molecules facilitating migration of T cells through the endothelium in response to homing signals released from inflamed tissues (42, 43). We previously demonstrated that patients with GI GVHD presented an increased frequency of CD146⁺CCR5⁺ T cells compared with patients without GVHD or nonenteritis GVHD, or with isolated skin GVHD (33). These observations suggest a role for the involvement of this population in late aGVHD manifestations. To evaluate the role of CD146- and CCR5-expressing cells in the pathogenesis of human cGVHD, we performed multiparameter flow cytometry on peripheral blood samples from 40 HSCT patients with and without active cGVHD (n = 20 patients/group) at the time of sample collection. Patient clinical characteristics are listed in Table 1.

First, we analyzed the expression of CD146 within CD4 conventional T cells (Tcon), defined as non-Tregs (i.e., excluding CD25⁺CD127low cells). CD146 was significantly upregulated in CD4 Tcon during sample collection. Patient clinical characteristics are listed in Table 1.

We also examined CD4⁺ Treg (defined as CD25⁺FoxP3⁺) and found, similarly to aGVHD (33), a significant upregulation of CD146 (median percentage: 21.65 during active cGVHD vs. 13.2 without cGVHD, P = 0.007) (Figure 1D) and an increased frequency of the double-positive subset (CD146⁺CCR5⁺) within the Treg subset (median percentage: 3.4 during active cGVHD vs. 2.1 without cGVHD, P = 0.007) (Figure 1E) during cGVHD. We observed similar findings when looking at absolute counts (Supplemental Figure 1, A–D; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.92111DS1). As we previously showed the increase of CD146-expressing subsets in a cohort of aGVHD, we analyzed our active cGVHD cohort, in which half had previously developed aGVHD. This analysis did not reveal any impact of prior aGVHD development (Supplemental Figure 1, E–J). Taken together, these data indicate that both CD146⁺ and CD146⁺CCR5⁺ T cell subsets with increased migration capacity are increased during cGVHD.

**CD146-expressing CD4⁺ T cells are skewed toward a Th17 profile during cGVHD.** We next evaluated whether CD146⁺ Tcons that were increased in patients with cGVHD expressed a specific polarization profile. Previous reports suggested that CD146⁺ subsets tended to be polarized toward a Th17 phenotype and function (44). As RORγt is a major transcription factor contributing to the Th17 polarization of a T cell subset, we assessed its expression level by flow cytometric quantification of mean fluorescent intensity (MFI) in healthy donor (HD) samples (Supplemental Figure 2, A–C) and confirmed the upregulation of RORγt in CD146⁺ CD4 (Supplemental Figure 2A) and CCR5⁺ CD4 (Supplemental Figure 2, B and C) Tcon, as well as Treg subsets, in addition to the CD146⁺CCR5⁺ Tcell subset (Supplemental Figure 2, B and C). We then evaluated the relative RORγt expression levels among HSCT patients with or without active cGVHD. In our cohort, RORγt expression was increased in active cGVHD patients compared with no cGVHD when examining effector CD4⁺ T cells (CD4⁺ Tcon, median RORγt MFI: 244 vs. 197, respectively, P = 0.0045) (Figure 2, A and B), as well as in both the CD146⁺ CD4 Tcon (median MFI: 291.5 vs. 244.5, respectively, P = 0.029) (Figure 2C) and CD146⁺CCR5⁺ CD4 Tcon (median MFI: 356 vs. 269.5, respectively, P = 0.042) subsets (Figure 2D). The same trends were observed for the CD4⁺ Treg (median RORγt MFI: 192 vs. 156.5 for active cGVHD and no cGVHD, respectively, P = 0.0066) (Figure 2E), as well as in CD146⁺ CD4 Treg...
CD146+CCR5+ CD4 T cell subsets harbor a mixed polarization. Because the chemokine receptor CCR5 is associated with Th1 polarization (45), we also evaluated T-bet expression, a canonical transcription factor of Th1 subset, within our population of interest. In HDs, CCR5 expression within Tcon had a greater impact on T-bet upregulation compared with CD146 (T-bet mean MFI: 661.5 in CD146–CCR5+ vs. 446.3 in CD146–CCR5–, P = 0.0078; 661.5 in CD146–CCR5+ vs. 520.9 in CD146+CCR5–, P = 0.07) (Supplemental Figure 2, D–F). We then evaluated IFN-γ production as a key Th1 signature cytokine. Consistent with T-bet upregulation data, the CD146–CCR5+-expressing subset produced a greater amount of IFN-γ compared with the reciprocal CD146+CCR5– subset (mean IFN-γ production: 66.15 vs. 23.69, respectively, P = 0.002) (Supplemental Figure 3, A–C). Together, our data showed in HD that CD146+CCR5+-expressing CD4+ T cells present both features of Th1 (T-bet/IFN-γ) and Th17 (RORγt/IL-17), with CD146 driving most of the Th17 phenotype (Supplemental Figure 2, B and C, and Supplemental Figure 3, D–F). As CD146+ and CD146+CCR5+ CD4 T cells are highly correlated (Spearman’s r = 0.81, P = 0.016, in HD), we evaluated whether CD146+-expressing CD4+ T cells were enriched for a Th1/Th17 subset previously described as pathogenic. When we analyzed CD146+ CD4 T cells, we observed a significant enrichment of a population secreting both cytokines IFN-γ/IL-17+ (mean percentage: 2.36% for CD146+ subset vs. 0.179% for CD146+, P = 0.002; and 4.579% for CD146+CCR5+ vs. 0.236% for CD4+ excluding the CD146+CCR5+ subset, P = 0.002) (Supplemental Figure 3, G–I). Interestingly, in our cohort, the Th1/Th17 (IFN-γ/IL-17+) subset within CD146+ CD4 T cells appeared to be associated with active cGvHD disease severity (Supplemental Figure 4) (median percentage of IFN-γ/IL-17+CD146+ in CD4+ T cells: 0.0152% for mild vs. 0.0438% for moderate, P = 0.064; 0.0438% for moderate vs. 0.075% for severe, P = 0.367; P = 0.048 between mild and severe).

### Table 1. Clinical characteristics of HSCT patients

<table>
<thead>
<tr>
<th></th>
<th>Active cGvHD n = 20</th>
<th>No cGvHD n = 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Median (range)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>59 (25.9–75.6)</td>
<td>60.4 (32.6–74.9)</td>
</tr>
<tr>
<td>Sex ratio</td>
<td>M/F</td>
<td></td>
</tr>
<tr>
<td>Conditioning regimen</td>
<td>MAC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Graft Source</td>
<td>BM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Donor</td>
<td>MUD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>mmUD</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Time from SCT (months)</td>
<td>Median (range)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>31.4 (11.5–123.8)</td>
<td>37.7 (12–140.9)</td>
</tr>
<tr>
<td>aGvHD (%)</td>
<td>Grade 2–4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 (50)</td>
<td>3 (15)</td>
</tr>
<tr>
<td>cGvHD NIH grade (%)</td>
<td>Mild</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 (40)</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 (40)</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 (20)</td>
<td>N/A</td>
</tr>
<tr>
<td>IST at the time of sample</td>
<td>Yes (%)</td>
<td></td>
</tr>
<tr>
<td>Steroid at the time of sample</td>
<td>Yes (%)</td>
<td></td>
</tr>
<tr>
<td>Mean steroid dose</td>
<td>mg/kg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.18</td>
<td>N/A</td>
</tr>
</tbody>
</table>

M, male; F, female; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; MRD, matched related donor; MUD, matched unrelated donor; mmUD, mismatched unrelated donor; PBSC, peripheral blood stem cell; SCT, stem cell transplantation; aGvHD, acute GvHD; cGvHD, chronic GvHD; IST, immunosuppressive therapy.
Figure 1. CD146 and CCR5 expression within CD4+ Tcon (non CD25hiCD127low within CD4+ T cells) and Treg (CD25hiFoxP3+ within CD4+ T cells) subsets. (A) Color plots representing the gating strategy of CD146-expressing cells according to CD45RA, and representative examples of CD146+ and CD146+CCR5+ subsets (in CD4+ T live lymphocyte gate) in 1 active cGvHD patient and 1 patient without cGvHD. (B–E) Data shown are dot plots (mean ± SEM) according to different clinical groups: No (n = 20) or active cGvHD (n = 20) and different clinical grades of cGvHD according to NIH criteria (mild, n = 8; moderate, n = 8; severe, n = 4). Unpaired t test comparing the frequencies between groups. Comparisons in B–E were analyzed using the Wilcoxon rank-sum test.
CD146 deficiency of donor T cells alleviates mouse cGVHD model that includes BO. Here, our data from human samples suggest a role for the CD146+ subset in the pathogenesis of cGVHD. Thus, we hypothesized that HSCT with CD146-KO donor T cells would preclude cGVHD generation using a well-established multiorgan cGVHD mouse model system that has BO as a prominent clinicopathological manifestation. We previously showed that B10.BR (H2k) recipients receiving BM and splenocytes from C57BL/6 (B6) donors developed a systemic multiorgan system cGVHD with BO mimicking human cGVHD (shown by pulmonary functional tests and lung fibrosis), representing a powerful tool to evaluate therapeutic interventions to better understand cGVHD pathogenesis and assess pharmacological interventions (12, 31, 46, 47). In this model, donor T cells mediate cGVHD via a RORγt-, STAT3-, and IL-17/IL-21–dependent mechanism (28, 31). In addition, pulmonary fibrosis was shown to depend upon Th17 (48) and donor macrophages in the context of cGVHD-related BO (29). When using splenocytes from CD146-KO vs. WT donors (together with WT BM), pulmonary functional tests (resistance, compliance, elastance) performed 2 months after transplant were each significantly improved and comparable with BM-only mice that did not develop cGVHD (Figure 3A). There was a statistical trend toward decreased lung histopathology (Figure 3B), while histopathology in other target organs (liver and colon) was not decreased (data not shown) in the CD146-KO group as compared with the WT group. Similarly, organ fibrosis assessed by trichrome staining of lung cryosections demonstrated markedly decreased collagen deposition with CD146-KO donors compared with WT (Figure 3C) and was quantitatively confirmed using a hydroxyproline assay to measure collagen burden (Figure 3D), whereas, consistent with histopathological analysis, no significant differences were seen in liver and colon fibrosis (data not shown). Flow cytometry of single-cell suspensions was performed to quantify the frequency of pathogenic T
cell subsets with Th17-related features within the lung. Similar to patient data, mice developing cGvHD had a significant increase in the IFN-γ+IL-17+ subset within both CD146+ and CD146+CCR5+ fractions, which was abrogated when using splenocytes from CD146-KO donors (Figure 4A). As we previously showed the involvement of macrophages in the lung fibrosis (29), we undertook the quantification of CD68 expression on lung cryosection and observed a marked increase in macrophage number during cGvHD that was alleviated in mice receiving CD146-KO splenocytes (Figure 4B). We also previously showed that development of BO during murine cGvHD was associated with increased T folliculocytes along with germinal center B cells (GC B cells) within the spleen (47). Splenic flow cytometry indicated no difference in TFH or GC B cells between the mice receiving CD146-KO vs. WT T cells (Figure 4C). Taken together, our data indicate that CD146 expression on donor T cells is necessary for cGvHD BO development and infiltration of pathogenic IFN-γ+IL-17+ subset and macrophages in the lung, rather than via direct effects on splenic TFH/GC B cell interactions.

Figure 3. CD146-expressing T cells are necessary for the development of cGvHD and lung fibrosis in a bronchiolitis obliterans model. B10.BR mice were transplanted with WT B6 BM without or with WT B6 T cells or B6 CD146–KO T cells as mentioned. (A) Mice were evaluated at day 60 for pulmonary function, measurement at day 56 after HCT, n = 8 per group. (B) Histopathology score of the lung at day 56 after HCT, n = 3 per group. (C) Lung sections were stained with trichrome for collagen deposition, 20× magnification. Representative data from 3 experiments. (D) Hydroxyproline quantitative measure in the lung of euthanized mice, n = 3–6 mice per group. Comparisons in A, B, and D were analyzed using the Wilcoxon rank-sum test.
Figure 4. CD146 deficiency of donor T cells is associated with decreased pathogenic IFN-γ+IL-17+ T cells and macrophage infiltration, but an intact TFH–GC B cell axis. (A) Flow cytometry was performed on single-cell suspension from lungs of different animal groups analyzed by flow cytometry at day 56, after stimulation with PMA-ionomycin in the presence of protein transport inhibitor. Data represent frequencies (mean ± SEM) of IFN-γ+IL-17+ subset within CD146+ (left panel) or CD146+CCR5+ fractions (right panel). (B) Lung cryosection were stained for CD68 expression (macrophages) together with DAPI to quantify cellular infiltrate. A representative example of immunofluorescence staining is shown of animals receiving BM only, BM + WT splenocytes (cGvHD), or BM + CD146-KO splenocytes (20× magnification). Automated quantification of macrophages relative to cellular infiltrate was performed to ensure reproducible analysis and is summarized in terms of frequencies (mean ± SEM). n = 3 mice per group, BM only n = 2. (C) CD146-KO does not impact T-B cross talk within lymphoid organ. GC B cells (CD19+GL7+Fas+) and TFH (CD4+CXCR5+PD1hiFoxP3) were analyzed by flow cytometry after spleen digestion at day 56 after transplant in animals receiving BM only, BM + WT splenocytes, or BM + CD146-KO splenocytes. n = 3–7 mice per group. Comparisons in A–C were analyzed using the Wilcoxon rank-sum test.
We and others have previously described the role of CD146 and ICOS stimulation in the development of human pathogenic IFN-γ/IL-17+ T cells (33, 49). Therefore, we sought to confirm the role of both CD146 and ICOS in murine IFN-γ/IL-17+ T cells by differentiating naive CD146-KO vs. CD146 WT T cells with either CD3/CD28 stimulation or CD3/ICOS stimulation. We showed that Th17 differentiation and ICOS stimulation significantly increased the number of cells coexpressing IL-17/IFN-γ and RORγt/IL-21 in cultures derived from naive CD146 WT T cells as compared with cultures derived from naïve CD146-KO T cells (Supplemental Figure 5). These data suggest a crucial role of CD146 in the development of IFN-γ/IL-17+ T cells and BO model that point to an effect on the Th17-related homing capacity of pulmonary macrophages, similar to the Th17-dependent BO observed in lung transplant (48).

TMP778 targeting of RORγt suppresses the development of pathogenic Th1/Th17 and CD146+CCR5+ CD4 T cells in vitro. We have now shown that CD146+CCR5+ CD4 T cells are Th17 committed, express higher levels of Th17 markers, and exhibit a pathogenic Th1/Th17 phenotype (coexpressing IL-17 and IFN-γ) (15). Toward clinical translation, we sought to determine whether potentially pathogenic Th1/Th17 cell differentiation could be blocked in vitro. Therefore, we measured the effect of TMP778, an inhibitor of the Th17 master transcription factor RORγt, on in vitro human Th1/Th17-polarized cells and CD146+CCR5+ CD4 T cells. Total CD4 T cells from HD were cultured under Th17 polarizing condition in the presence of increasing doses of TMP778 or vehicle control DMSO. TMP778 significantly reduced the frequency of Th17 and CD146+CCR5+ CD4 T cells in a dose-dependent manner (Figure 5A). In addition, the frequency of CD146+CCR5+ T cells was also inhibited in a dose-dependent manner (Figure 5B). Similarly, TMP778 at a concentration of 0.1 µM and 1 µM significantly inhibited the generation of Th1/Th17 and CD146+CCR5+ CD4 T cells in allogeneic mixed lymphocyte reaction (MLR) cultures (Supplemental Figure 6). Together, our results indicate that TMP778 can suppress not only the differentiation of Th17, but also the development of Th1/Th17 and CD146+CCR5+ CD4 T cells in vitro.

Pharmacological and neutralizing antibody inhibition of RORγt, STAT3, or IL-17 reverses established mouse cGvHD. Results above suggested a relationship between CD146 and Th17 polarity. Thus, we evaluated the in vivo cGvHD effect of pharmacological inhibition of RORγt with a small-molecule inhibitor that showed strong efficiency in other Th17-driven disease (40) and under the in vitro Th17 polarizing conditions from HD described immediately above. TMP778 interacts with RORγt to hamper its transcription factor activity and, consequently, IL-17 secretion (40, 41). Toward clinical translation, we treated recipients with TMP778 beginning on day 28 (d28) at the time of established cGvHD. TMP778 treated mice showed a significant improvement of pulmonary function tests at d60, reaching the level of recipients receiving CD146-KO splenocytes or BM only (Figure 6). Similarly, administration of an anti–IL-17 blocking antibody on d28 significantly improved each of the pulmonary function test parameters, alleviating BO-related cGvHD (Figure 6).

Discussion
In the present study, we sought to identify and characterize a new T cell subset involved in human and murine cGvHD. Defining cellular biomarkers of cGvHD, such as T cell subsets, remains a major goal in order to improve our understanding and to develop targeted therapies. Here, we define a pathogenic CD4 T cell population based on the expression of CD146 and CCR5 reflecting its capacity to migrate to inflamed tissue and to interact with endothelial barriers in the context of alloreactivity.

CD146 (also called melanoma cell adhesion molecule [MCAM]) is a cell adhesion glycoprotein expressed on lymphoid cells, endothelial cells, smooth muscle cells, and tumor cells, and displays homophilic or heterophilic interaction (50). It has been shown to play a major role in T cell migration through interaction with endothelial cells (33, 43). Hence, CD146 expression on T cells has been shown as a surrogate of subsets with transendothelial migration capacity (33) during the course of inflammation. Our study revealed that patients with active cGvHD had significantly higher CD146 expression in CD4 T cells, including both Tcon and Treg subsets.

CD146 can be upregulated on T cells upon TCR or mitogen stimulation, reflecting T cell activation. When binding CD146 through homophilic interaction, downstream transducing signals induce phosphorylation of cellular proteins such as Pyk2, focal adhesion kinase, and paxillin, thus promoting transendothelial migration (43). Similarly, we also evaluated another subset of CD146-expressing cells, the CD146+CCR5 double-positive CD4 T cells, which were increased in patients with cGvHD. These CD146-expressing CD4 T cells (including CD146+CCR5+) exhibited Th17 features. Specifically, CD146+CD4 T cells express a significantly higher concentration of RORγt and IL-17 intracellular expression upon stimulation. Previous reports
showed that CD146-expressing T cells upregulated IL-17, IL-22, and CCR6 mRNA (44). Here, we observed in patients with active cGvHD an increased expression of ROR\(\gamma\) within CD146\(^+\) or CD146\(^+\)CCR5\(^+\) T cells (Tcon and Treg), suggesting a strong Th17 signature during cGvHD. The role of CD146 in Th17 differentiation remains poorly understood; however, we previously showed using shRNA (CD146) experiments that naïve CD4 T cells cultured under Th17 polarizing conditions had reduced capacity to produce IL-17 and IFN-\(\gamma\) (33). We have now confirmed these data using murine naïve CD146-KO T cells. Thus, CD146 expression appears as a surrogate marker for IL-17 and IFN-\(\gamma\) pathogenic subset without precluding for a mechanistic role. Interestingly, CD146-expressing Treg showed a decreased suppressive capacity consistent with the upregulation of ROR\(\gamma\). This underlines the altered homeostasis between Treg and Tcon previously described (5), along with the potential impact of a defective function within regulatory subsets during cGvHD.

CCR5 is a chemokine receptor for CCL14 and CCL5, secreted at inflammatory sites, shown to promote the homing of inflammatory Teff subset, such as Th1 (45). We showed that CCR5-expressing CD4 T cells expressed greater levels of T-bet and IFN-\(\gamma\). CCR5-expressing CD4 T cells have been evaluated in the context of aGvHD, but no reports investigated its implication on circulating T cells during cGvHD. Morita et al. reported the expression of CCR5 by a lymphoid infiltrate within the skin of patients with cGvHD, suggesting its role in the migration of T cells toward inflammatory sites (51). Interestingly, CD146/CCR5 double-positive CD4 T cells appeared to be enriched for a subset with a mixed polarization of Th1 and Th17, as attested by the coexpression of ROR\(\gamma\)/T-bet and IFN-\(\gamma\)/IL-17. This subset has been shown to harbor a pathogenic role in several autoimmune diseases (52, 53). Indeed, Annunziato et al. previously showed that the Th1/Th17 subset showed increased cytotoxic capacity and lower susceptibility to the Treg suppressive activity (52). Comparably, Brüggen et al. observed a mixed Th1/Th17 signature in the skin of patients with lichenoid cGvHD (32).

To understand the role of CD146-expressing T cells in the pathogenesis of cGvHD, we utilized donor CD146-KO splenocytes in our multiorgan model of cGvHD with BO manifestations (46). We observed a significant alleviation of BO-cGvHD. Furthermore, we observed an increase in the pathogenic IFN-\(\gamma\)/IL-17\(^+\) subset within both CD146\(^+\) and CD146\(^+\)CCR5\(^+\) fractions in the lung of animals developing cGvHD that was alleviated when using CD146-KO splenocytes. In our model using splenocytes from CD146-KO mice, the remaining CD146\(^+\) or CD146\(^+\)CCR5\(^+\) fractions, thus, appeared to differentiate from WT BM lymphoid progenitors. However, the overall decrease in CD146\(^+\) and CD146\(^+\)CCR5\(^+\) subsets may be consecutive to thymic injury from cGvHD and reduced production of T cells.
We previously showed, in this model, the requirement of alloantibody production from donor B cells differentiated during GC reaction, where TFH cells play a central role (46, 47). However, we didn't observe any impact on TFH and GC B cell frequencies between CD146-KO and WT splenocyte conditions. This suggests that CD146-KO does not impair T-B cross talk and B cell differentiation into GC B cells and plasmablasts. Instead, CD146-KO appears to hamper Th17 cells that harbor profibrotic functions toward lung tissue, as we and other have previously shown (54, 55), thus explaining the improvement of pulmonary function parameters. As we previously reported the role of macrophages in the lung fibrosis, we analyzed macrophage infiltration using immunofluorescence and showed an increased infiltrate in murine cGvHD that was alleviated in mice receiving CD146-KO splenocytes. This underlines the central role of Th17-polarized subsets, which harbor the capacity to secrete chemokines (CXCL8, CCL20, GM-CSF, IL-1β, and TNF-α), thus promoting a proinflammatory environment (48).

Because the CD146-expressing subset is Th17 polarized and appears as a key player of cGvHD, we tested a small-molecule inhibitor of the RORγt pathway to specifically target the Th17-derived subset. TMP778 is a pharmacological inhibitor that binds to RORγt to block downstream gene expression, such as IL-17A/F, IL-22, IL-23R, and CCR6, but also prevent a RORγt inhibitory effect on T-bet and GATA3 gene expression (40). TMP778 suppressed IL-17 and IFN-γ coproduction and diminished the CD146/CCR5 double-positive subset not only from differentiated Th17 in vitro (ICOS-induced), but also in an alloreactive context (MLR). Importantly, TMP778 administration to mice receiving WT splenocytes alleviated lung cGvHD. Similarly, we observed BO alleviation when using anti–IL-17 blocking antibody, partly mimicking the downstream effect of TMP778. In addition, RORγt program expression is dependent on the STAT3 axis (56), as attested by reports on STAT3 deficiency (57) or STAT3 inhibitors (38, 58) inducing RORγt inhibition and Th17 deficiency. Thus, we also administered Cucurbitacin I, a potent STAT3 inhibitor, to evaluate upstream RORγt inhibition and observed BO alleviation at a similar level to TMP778 or CD146-KO (data not shown).

In summary, our study provides data supporting the role of CD1460-expressing CD4 T cells in the pathogenesis of cGvHD, showing enhanced Th17 features also involved in other autoimmune diseases (44, 59). This proposed cellular biomarker of cGvHD would be required to be prospectively validated in order to justify clinical applications of RORγt inhibitors showing promising preclinical results.

**Methods**

Supplemental Methods are available online with this article.

*Mouse.* C57BL/6 (B6; H2b) mice were purchased from the National Cancer Institute. H2b mice were purchased from Jackson Laboratories. CD146-KO mice (on the H2b background) were provided for this study by Hong Wei Chu (National Jewish Health, Denver, Colorado, USA). Mice were housed in a specific pathogen–free facility.

**BM transplant and therapeutic interventions in mice.** H2b recipients were transplanted as previously described (31). Briefly, mice were given 2 doses of cyclophosphamide (120 mg/Kg) i.p. and total body irradiation (TBI)
Mice were transplanted with $1 \times 10^7$ WT B6 BM cells supplemented with or without $0.6 \times 10^6$ to $0.8 \times 10^6$ T cells from either WT or CD146-KO B6, where indicated. Where specified, cGvHD recipients were stained with CD4, CD25, CD127, and CD146. The following subsets were sorted using the FACSAria (BD Biosciences) assay: PBMC from leukopacks (HDs) were enriched for CD4+ T cells (MACS-negative selection) and analyzed using LSR Fortessa (BD Biosciences) and FlowJo v.10 software (Tree Star Inc.). For Treg suppression assay: PBMC from leukopacks (HDs) were enriched for CD4+ T cells (MACS-negative selection) and stained with CD4, CD25, CD127, and CD146. The following subsets were sorted using the FACSAria (BD Biosciences): Tcon (CD8 CD14 CD19 CD4+CD25 CD127+), Treg CD146+ (CD8 CD14 CD19 CD4+CD25 CD127 CD146+), and Treg CD146 (CD8 CD14 CD19 CD4+CD25 CD127 CD146+). Purity of sort-
ed subsets was > 95%. Tcon were stained with CFSE (1 μM). Treg and Tcon subsets were cocultured for 5 days at different ratios upon stimulation with coated αCD3 (final concentration [CF] = 5 μg/ml) and soluble αCD28 (CF = 3 μg/ml). At d5, cells were stained with a viability dye and read on Fortessa. For suppression, formula = (Tcon alone − [Tcon + Treg])/Tcon alone × 100.

ROtyt and IL-17 targeting reagents. TMP778 powder, synthesized by GlaxoSmithKline and provided by Jianfei Yang (Tempero Pharmaceuticals a company of GSK, Cambridge, Massachusetts, USA), was dissolved in DMSO at 808.76 mM and stored at –80°C as aliquots. Immediately before use, an aliquot of TMP778 stock solution was diluted in DMSO to 0.01 mM, 0.1 mM, and 1 mM and then further diluted by a factor of 1,000 in culture medium to final concentrations of 0.01 μM, 0.1 μM, and 1 μM, respectively. DMSO at 0.1% was used as vehicle control. For in vitro treatment, PBMCs were prepared from leukopacks of HD (Central Indiana Blood Bank) by Ficoll-Paque density-grade centrifugation (GE Healthcare). Total CD4 T cells were positively isolated using human CD4 microbeads (Miltenyi Biotec) and activated for 6 days with anti-CD3/anti-ICOS antibody-coated Dynabeads M-450 Tosylactivated (Invitrogen) at a bead/cell ratio of 1:5 under the Th17-polarizing conditions: IL-1β (20 ng/ml), IL-6 (30 ng/ml), IL-23 (30 ng/ml), TGF-β (2 ng/ml), and neutralizing antibodies against IL-4 (5 μg/ml) and IFN-γ (2 μg/ml) (eBioscience). Exposure to differentiating cytokines (all from R&D Systems) and blocking antibodies was maintained throughout the culture period. For allogeneic MLR, irradiated (3,000 cGy) PBMCs from one donor were used as the stimulator and mixed in a 1:1 ratio with PBMCs from another donor, used as the responder for 8–10 days. TMP778 or DMSO vehicle control was added to the Th17 and MLR cultures on d0, replenished every 3 days, and maintained throughout the culture period. TMP778-treated Th17 or MLR cells were analyzed by flow cytometry for cell-surface expression of CD4, CD146, and CCR5. For intracellular cytokine staining of IL-17 and IFN-γ, cells were stimulated with PMA (50 ng/ml; Sigma-Aldrich), ionomycin (1 μg/ml; Sigma-Aldrich), and brefeldin A (3 μg/ml) (eBioscience) for 5 hours. Intracellular cytokines were stained with the intracellular fixation and permeabilization buffer set (eBioscience). All staining antibodies were obtained from eBioscience. Stained cells were analyzed using an Attune Flow Cytometer (Invitrogen) and FlowJo software.

Statistics. Baseline clinical characteristics were compared between groups using either Fisher’s exact test or χ² test for categorical variables or Wilcoxon rank-sum test for continuous variables. Phenotypic and functional data were compared using Wilcoxon rank-sum test for unpaired group comparison and Wilcoxon signed-rank test for paired comparison. Prior to analysis, the normality assumption was examined. All tests were 2-sided at the significance level of 0.05. For Figure 6, each subplot involved 2 groupwise comparisons. To account for the type I error inflation due to multiple comparisons, we applied the Bonferroni correction. For Figure 5 and Supplemental Figure 6, we evaluated the mean linear rate of change of IL-17 IFN⁺ and CD146⁺CCR5⁺ as a function of different concentrations of a ROtyt inhibitor, TMP778 (from 0–1 μM). To statistically evaluate this change, we performed a 1-sample t test comparing the mean linear rate of change (e.g., slope), which was estimated for each value separately using least square estimation, to 0.

Statistical analyses and graphs for Figures 1–4 were performed using Prism software (GraphPad), and data are presented as mean ± SEM. Statistical analyses for Figures 5 and 6 and Supplemental Figure 6 were performed using STATA 14 for Windows.

Study approval. All studies were conducted in accordance with the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals and were reviewed by the University of Minnesota institutional animal care and use committee (IACUC 1504-32476A) and by Indiana University (IACUC 10488). All patients and HDs were enrolled in clinical research protocols approved by the Human Subjects Protection Committee of the Dana-Farber/Harvard Cancer Center (IRB 01-206). Written informed consent was obtained prior to sample collection, in accordance with the Declaration of Helsinki. The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents.

Author contributions
EF, KP, RF, BG, TA, WL, LL, GB, DJ, ELE, and JD performed experiments, analyzed data, and participated in manuscript preparation. HWC provided CD146-KO mice. ML and JY provided TMP778 and edited the manuscript. DSW, PB, KG, GRH, and KPAM participated in study design and manuscript preparation. CSC, JHA, and RJS provided human samples and assisted in manuscript preparation. JR, SP, and BRB participated in study design and manuscript preparation and obtained funding for the study. JSS participated in study design and manuscript preparation. JK provided human samples and assisted in manuscript preparation.
Acknowledgments

This work was supported by the NIH (R01 CA168814, R01 CA183559, R01 CA183560, P01 CA142106, P01 AI056299), the Leukemia & Lymphoma Society Scholar Award (1293-15), the Lilly Physician Scientist Initiative Award, Cancer Biology Training grant T32 CA009138, the Ted and Eileen Pasquarrello Research Fund, the MD-PhD program (University Hospital of Bordeaux, France), and the French Society of Hematology (SFH) and Association Laurette Fugain. Immunofluorescence imaging was provided by the University of Minnesota - University Imaging Centers, http://uic.umn.edu.

Address correspondence to: Bruce R. Blazar, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, MMC 109, Minneapolis, Minnesota 55455, USA. Phone: 612.626.2734; Email: blaza001@umn.edu. Or to: Sophie Paczesny, Indiana University School of Medicine, 1044 W. Walnut Street, Room R4-425, Indianapolis, Indiana 46202, USA. Phone: 317.278.5487; Email: sophpacz@iu.edu.


